Legal notices

This Web site is provided by Incyte Corporation ("Incyte").

PLEASE READ AND REVIEW THE FOLLOWING TERMS CAREFULLY BEFORE USING THE WEB SITE. The following terms govern your use of the Web site, and by using the Web site you agree to be bound by and to comply with such terms. If you do not agree, you may not access or use the Web site. Incyte reserves the right to modify these terms from time to time without notice.

Use of the Web Site

While Incyte uses reasonable efforts to include up-to-date and accurate information on the Web site, INCYTE MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE ACCURACY, COMPLETENESS OR SUITABILITY OF THE INFORMATION MADE AVAILABLE ON THE WEB SITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE INFORMATION ON THE WEB SITE IS PROVIDED TO YOU AS IS. Incyte disclaims any and all liability related to use of the Web site or any Web site linked to this notice. Incyte shall not have any obligation to update the Web site. Your access and use of the Web site, including without limitation, the information made available on the Web site, is at your own risk. You agree that you will not make any claim against Incyte based on your access or use, or inability to use, the Web site or its contents. Incyte shall not be liable in any manner whatsoever for any direct, indirect, consequential, incidental, special or punitive damages arising out of your access, use or inability to use the Web site or its contents, or errors or omissions in the content thereof, including without limitation, loss of use, data or profits, whether in an action based on contract, negligence or other tort.

The Web site and the information contained or referenced on the Web site is intended for informational, personal and non-commercial purposes only. The Web site does not provide medical or professional services or advice and should not be relied upon as the basis of any healthcare decision. Persons requiring diagnosis or treatment or with questions specific to an individual are urged to contact their healthcare provider.

The Web site is only intended for use by U.S. residents who are at least eighteen (18) years of age. You should not construe anything on the Web site as a promotion of or solicitation for any product or service that is not authorized by the laws and regulations of the jurisdiction in which you are located.

You may not use the Web site or its contents for any purpose that is unlawful.

Copyright and other intellectual property rights

The Web site, and the information which it contains, is the property of Incyte, and is protected from unauthorized copying and dissemination by United States copyright law, international conventions and other intellectual property laws. The trademarks, service marks, logos, or other intellectual property displayed on the Web site are owned by Incyte except as otherwise noted. Nothing on the Web site should be construed to grant any license or right in or to any trademarks, service mark, logos or other intellectual property rights. All rights are reserved by the owners of each trademark, service mark, logo, or other intellectual property, except as otherwise described in this notice.

Links to third-party Web sites

As a convenience to you, we may provide links to third-party Web sites that may be of interest to you. Such third-party Web sites are subject to their own terms of use. Incyte does not monitor, approve, endorse, warrant or sponsor any information, conclusions, recommendations, products or services described on those Web sites. Incyte shall have no responsibility or liability for your use of or access to such third-party Web sites.

Information submitted to Incyte

Should you submit any information (eg feedback, suggestions, ideas or comments) to Incyte via the Web site, such information, except for personally identifiable information which is covered by Incyte's Privacy Policy, will be deemed to be Incyte's property and non-confidential; and Incyte shall be free to use, reproduce, disseminate, distribute and otherwise exploit such information without limitation, and without providing any compensation to you. Incyte shall be free to use any ideas, concepts, know-how, techniques or methods contained in such information for any purpose, and in any manner, whatsoever. By submitting such information you warrant and represent that you are the owner of all rights in such information. Under no circumstances shall you use the Web site or any of Incyte's email or other addresses to send Incyte proprietary or confidential information belonging to a third party.

Privacy policy

See Incyte's Privacy Policy for the terms and disclosures relating to the collection and use of your personal information.

No offer and no solicitation

The information provided on the Web site does not constitute an, and is not provided in relation to any, offer of or solicitation for the purchase or disposal of, trading or any transaction in any Incyte securities. Investors must not rely on this information when making investment decisions.

Miscellaneous

Incyte reserves the right to change the content of the Web site at any time without notice to you. Incyte reserves the right to terminate your access or use of the Web site at any time. If your violation of these terms causes harm to others, you shall indemnify and hold Incyte harmless from and against any and all liabilities, losses, damage and expenses related thereto. These terms shall be governed by the laws of the State of Delaware, without giving effect to its conflict of laws principles. You hereby submit to the jurisdiction of the state and federal courts in Wilmington, Delaware in any proceeding relating to the Web site or its contents. These terms set forth the entire agreement between you and Incyte with respect to the subject matter hereof.

Copyright notice applicable to Web site

Copyright © 2004-2014 Incyte Corporation. All rights reserved.

INDICATIONS AND USAGE

Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.

IMPORTANT SAFETY INFORMATION

  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 x 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk‐benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi‐organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non‐melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • The three most frequent non‐hematologic adverse reactions (incidence >10%) were bruising, dizziness and headache
  • A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breast‐feed

Please see Full Prescribing Information for Jakafi.

 
IMPORTANT SAFETY INFORMATION
 
INDICATIONS AND USAGE
Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.
IMPORTANT SAFETY INFORMATION
  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 x 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk‐benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi‐organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non‐melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • The three most frequent non‐hematologic adverse reactions (incidence >10%) were bruising, dizziness and headache
  • A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breast‐feed

Please see Full Prescribing Information for Jakafi.